NASDAQ:VKTX
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.'s revenue was $0 in fiscal 2025. The diluted share count rose 3.3%.Summary generated from Viking Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 11, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−47.3%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+3.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −56 | −70 | −101 | −151 | −393 |
| Net income | −55 | −69 | −86 | −110 | −360 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KEntry into a material agreement
Sep 28, 2026 - 8-KOther events
Sep 22, 2026 - 4Insider transaction report
Aug 7, 2026 - 4Insider transaction report
Jul 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 29, 2026 - 8-KResults of operations and financial condition
Jul 29, 2026 - 8-KResults of a shareholder vote
May 26, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026